Biogenvs.United Therapeutics
BIIB vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 1.4× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (17.8 vs 38.4); year to date, Biogen leads (+26.2% vs +11.9%).
Side by side
| BIIB | UTHR | |
|---|---|---|
| Market cap | $32.1B | $23.4B |
| Price | $218.43 | $532.78 |
| Today | −1.7% | −2.2% |
| Return YTD | +26.2% | +11.9% |
| Return 1Y | +45.9% | +19.3% |
| Since June 26, 2026 | +1.1% | −1.8% |
| P/E | 38.4 | 17.8 |
| P/S | 3.2 | 7.4 |
| P/B | 1.7 | 3.7 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More BIIB & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.